Niepubliczny Zakład Opieki Zdrowotnej "terapia Optima"
- Address
- Medyków 18, 40-762 Katowice, Poland
Niepubliczny Zakład Opieki Zdrowotnej terapia Optima
NZOZ terapia Optima is a specialized medical research facility focused on investigating metabolic disorders and lipid metabolism abnormalities. The center demonstrates expertise in conducting clinical trials for novel therapeutic interventions targeting complex metabolic conditions that pose significant cardiovascular risk.
- Severe hypertriglyceridemia and lipid disorders
- Advanced cardiometabolic disease prevention
- Novel RNA-based therapeutic strategies
The facility's research portfolio includes evaluation of innovative treatments such as plozasiran, demonstrating their commitment to advancing therapies for severe hypertriglyceridemia (SHTG). Their work focuses on reducing fasting serum triglyceride levels, a critical factor in preventing acute pancreatitis and cardiovascular complications in high-risk patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Arrowhead Pharmaceuticals Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Arrowhead Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Niepubliczny Zakład Opieki Zdrowotnej "terapia Optima"
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues | 2 | Unknown | 2024-10-31 | 2025-12-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.